Repligen Corp. (RGEN) stock forecast and price target
Price $167.79 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($167.79)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $2.07 | +21.2% | $849M |
| Next fiscal year ends December 31, 2027 | $2.65 | +27.9% | $1.1B |
| Next quarter ends December 31, 2026 | $0.52 | +6.9% | $241M |
| Quarter after ends March 31, 2027 | $0.60 | +24.0% | $250M |
Consensus of the analysts covering Repligen, updated daily. In the last 30 days 8 estimates were raised and 5 lowered.
Our model vs. Wall Street
Analysts see 21.1% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Repligen’s intrinsic value about 76% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Repligen stock price target?
The average 12-month target from 19 analysts is $203.21, 21.1% above the current price of $167.79 Targets range from $175.00 to $235.00.
Is Repligen a buy according to analysts?
The consensus rating is “Buy” (3 strong buy, 13 buy, 4 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Repligen expected to earn?
Analysts expect EPS of $2.07 for the fiscal year ending December 31, 2026 and $2.65 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.